Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization;Evolución clínica de los pacientes psoriásicos tratados con efalizumab al suspender el fármaco.

Actas dermo-sifiliográficas

Volumn 101, Issue 5, 2010, Pages 421-427

  Baniandres O ^a   Pulido, A ^b   Silvente, C ^b   Suarez R ^b   Lazaro P ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; DRUG RECALL; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PSORIASIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SAFETY-BASED DRUG WITHDRAWALS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957332460     PISSN: None     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70665-X     Document Type: Article

References (0)